Panacea Stars
Status
ACTIVE
Global HQ
United Kingdom
Countries of investment
- United Kingdom
Investment stages
- Pre-Seed
- Seed
Industries
- Health Tech
- Biotechnology
- AI
- Data Science
About
Panacea Stars is a venture capital firm based in Oxford, United Kingdom, committed to transforming scientific innovations into successful companies. They support scientrepreneurs by providing nondilutive translational funding, equity investment packages, commercialization services, executive mentorship, and global networks. Notable companies in their portfolio include DJS Antibodies, Enterobiotix, Phenomic AI, Mytos, Feebris, VisusNano Ltd., Cambridge Cancer Genomics, and SAVA Health. Their multifaceted approach helps derisk developments and fasttrack innovations to market, focusing primarily on the health tech, biotech, and AI industries.
Panacea Stars is a venture capital firm based in Oxford, United Kingdom, committed to transforming scientific innovations into successful companies. They support scientrepreneurs by providing nondilutive translational funding, equity investment packages, commercialization services, executive mentorship, and global networks. Notable companies in their portfolio include DJS Antibodies, Enterobiotix, Phenomic AI, Mytos, Feebris, VisusNano Ltd., Cambridge Cancer Genomics, and SAVA Health. Their multifaceted approach helps derisk developments and fasttrack innovations to market, focusing primarily on the health tech, biotech, and AI industries.
Investment Thesis
They collaborate with scientrepreneurs to transform bold visions into thriving companies that improve peoples lives.
Manager's Experience
With extensive experience in the private equity landscape, the fund manager has successfully executed over 50 deals, predominantly in technology and healthcare sectors across North America and Europe. Their strategic style emphasizes a data-driven approach, enabling them to identify and capitalize on emerging trends. Noteworthy exits include several high-profile acquisitions, showcasing their adeptness at navigating various investment stages, from growth equity to buyouts. This operator-first mindset has consistently driven value creation and robust returns for stakeholders.
Portfolio
Cambridge Cancer Genomics
CRIAM
Cytera Cell Works
DJS Antibodies
Enterobiotix
Feebris
Hutano Diagnostics
Innersight Labs